However, CD25 is not a specific marker to CD4+Treg, and the combination of CD25-targeted therapy with tumor vaccines can suppress the generation of tumor-specific T cells (45), limiting the application of CD25 antibodies. The gene discussed is IL2RA; the disease is neoplasm.